Hartmut Voss, Ph.D. is responsible for the scientific evaluation of biotechnology and biopharmaceutical companies at Dievini. He obtained his Ph.D. at the European Molecular Biology Laboratory (EMBL) in Heidelberg after having studied biology at the University of Kaiserslautern. He was co-founder of LION bioscience AG (now Sygnis Pharma AG) in 1997 where he held various senior management positions.
Prof Peter Krammer, M.D. is coordinator of the research program Tumor Immunology at the German Cancer Research Center (DKFZ) and Head of the Division of Immunogenetics. He is one of the world’s most renowned apoptosis researchers and has been awarded numerous prestigious awards and honours, such as the Robert Koch Prize, the Avery-Landsteiner Prize, the Ernst Jung Prize and the Order of Merit of the Federal Republic of Germany.
Martin Bürmann, J.D., is partner of the law firm Rittershaus in Mannheim. He studied law at the University of Heidelberg, was accredited as Attorney At Law in 1998, and obtained his J.D. in 1991 at the University of Augsburg. He is specialized in corporate law, private equity transactions, and trade sales and has been advising biotechnology companies since 1999.